Radiotherapy Combined with Intralesional Immunostimulatory Agents for Soft Tissue Sarcomas.
Semin Radiat Oncol
; 34(2): 243-257, 2024 Apr.
Article
in En
| MEDLINE
| ID: mdl-38508788
ABSTRACT
Immunotherapy has shifted the treatment paradigm for many types of cancer. Unfortunately, the most commonly used immunotherapies, such as immune checkpoint inhibitors (ICI), have yielded limited benefit for most types of soft tissue sarcoma (STS). Radiotherapy (RT) is a mainstay of sarcoma therapy and can induce immune modulatory effects. Combining immunotherapy and RT in STS may be a promising strategy to improve sarcoma response to RT and increase the efficacy of immunotherapy. Most combination strategies have employed immunotherapies, such as ICI, that derepress immune suppressive networks. These have yielded only modest results, possibly due to the limited immune stimulatory effects of RT. Combining RT with immune stimulatory agents has yielded promising preclinical and clinical results but can be limited by the toxic nature of systemic administration of immune stimulants. Using intralesional immune stimulants may generate stronger RT immune modulation and less systemic toxicity, which may be a feasible strategy in accessible tumors such as STS. In this review, we summarize the immune modulatory effects of RT, the mechanism of action of various immune stimulants, including toll-like receptor agonists, and data for combinatorial strategies utilizing these agents.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Sarcoma
Limits:
Humans
Language:
En
Journal:
Semin Radiat Oncol
Journal subject:
NEOPLASIAS
/
RADIOLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Nueva Caledonia
Publication country:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA